New Linkers for Antibody Drug Conjugates

Out-licencing platform technology and partnering opportunity for new ADC development projects

SUMMARY OF INVENTION

Researchers at NORUT Biotech in Tromsø, Norway have developed a new set of heterobifunctional self-eliminating linkers for use in ADC conjugation, amongst other applications.

Our technology combines known cysteine-based conjugation chemistry with novel and an innovative self-releasing cyclisation technology, that provides an ADC that leaves the unmodified drug at the target site. Linker release is initiated by a validated disulfide bond cleavage mechanism, which can be modulated for stability.

A subsequent intramolecular reaction by the linker yields an unmodified cytotoxin. Carbonate or carbamate linkage options provide new possibilities to adjust ADC stability and utilize both hydroxyl- and amine-containing payloads

ADVANTAGES & APPLICATIONS

  • Novel releasable linkers technology for ADCs requiring the delivery of unmodified drugs
  • Conjugation chemistry allows for easy adoption into established laboratory routines
  • Wide range of linkers for use with various (i) delivery vectors, (ii) types of ADC drugs, and (iii) linkage stability requirements
  • Alternative to current proprietary self-releasing (e.g. cathepsin based) technologies

We foresee a number of ways our linker can be used in the ADC industry

  • ADC development
  • Toxicity masking

DEVELOPMENT & IP STATUS

Our linkers have been sythesised and we have several samples available for testing.  The linker technology is protected under patent pending.

Key info


Origin



Inventor(s)

Johannes Eksteen
Myagmarsuren Sengee
Leiv Sydnes




Contact Person


Magnus Seppola
Business Developer
(+47) 95112385
LinkedIn
magnus(a)norinnova.no

Norinnova Technology Transfer AS